Stanford researchers have tested a nasal spray vaccine in mice that trains lung immunity to fight a range of respiratory threats, showing protection against multiple viruses, some bacteria and even common allergens for months; the work is preclinical, promising but preliminary, and will need careful human trials before any rollout.
The team used an intranasal approach, putting a small dose directly into the nose of mice to focus the immune response where respiratory infections start. Vaccinated animals were challenged with different pathogens and showed strong resistance that lasted through the observation period. That localized stimulation is the key idea: prepare the lungs to act fast when a threat arrives.
In experiments the vaccinated mice survived exposures that left unvaccinated animals weak and inflamed, with clear differences in lung pathology. Researchers reported that vaccinated animals maintained weight and had healthy-looking lungs long after infection. Those outcomes suggest the intervention alters early immune behavior rather than chasing a single pathogen.
The investigators stress that the vaccine does not aim at one virus but instead “reprograms” lung immunity to respond broadly to incoming threats. “By reprogramming the innate immune cells that act within hours of infection, the vaccine prepares the lungs to fight off many different respiratory viruses, even new ones,” he said. Training innate cells this way could blunt the impact of viruses before they get established.
Protection in the study extended beyond familiar respiratory viruses to include certain hospital-associated bacteria and common allergens, hinting at a multi-threat defense. The mice showed resistance to bacterial strains that often complicate hospital stays and to allergens that drive seasonal symptoms. That combination—viral, bacterial and allergic protection—would be a major shift if replicated in people.
Investigators describe this as a proof of concept rather than a finished product, pointing to both promise and important limits. The work was done in animal models, and animal immune systems are not carbon copies of ours, so responses can differ. “While the results are encouraging, additional studies are needed to determine safety, optimal dosing and effectiveness in people,” he added.
The research team envisions a future where a simple nasal spray given before peak seasons could reduce the need for multiple separate shots. “Imagine getting a nasal spray in the fall months that protects you from all respiratory viruses, including COVID-19, influenza, respiratory syncytial virus and the common cold, as well as bacterial pneumonia and early spring allergens,” the researcher said. If achievable, that approach would change how routine respiratory protection is delivered.
Mechanistically, the results suggest the immune system can be nudged toward broader antiviral readiness in lung tissue. The study notes that tissues themselves host immune cells that can be trained to respond more generally when triggered the right way. The researchers write that the immune system can “be trained to mount a more generalized antiviral defense in the lungs,” Pulendran added.
Experts not involved in the work urge caution and a measured timeline before human use is considered. “This process is a fascinating concept, and the study is very interesting, but many additional steps need to be completed successfully and safely before this could be considered in humans,” one outside clinician said. It will likely require years, additional costly studies and careful safety checks to move from mice to people.
The team plans human testing next, pending funding and regulatory pathways, and they estimate several years before a licensed product could exist. They note that translation to people will require precise dosing studies, safety monitoring and proof that broad protection holds across diverse human populations. “Our goal is not to replace current vaccines, but to complement them by developing strategies that could provide an added layer of protection against a wide range of respiratory threats, including future pandemics,” Pulendran added. “Translation to humans will require careful clinical testing.”
The study received support from national research grants and philanthropic endowments, which enabled the preclinical work and set the stage for further development. Researchers emphasize that current medical advice and approved vaccines remain the backbone of public health while this line of inquiry advances. If subsequent trials confirm safety and benefit, a broadly acting nasal vaccine could become a valuable additional tool against seasonal and emerging respiratory threats.
